Journal Article

Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors

Uhlig, Ria, Dum, David, Bernreuther, Christian, Sauter, Guido, Möller, Katharina, Höflmayer, Doris, Fraune, Christoph, Lebok, Patrick, Gorbokon, Natalia, Weidemann, Sören, Büscheck, Franziska, Hube-Magg, Claudia, Burandt, Eike, Minner, Sarah, Krech, Rainer, Marx, Andreas, Wilczak, Waldemar, Weitbrecht, Timo, Steurer, Stefan, Hinsch, Andrea, Luebke, Andreas M., Kluth, Martina, Menz, Anne, Clauditz, Till, Krech, Till, Simon, Ronald

2021

Overview

Background Cytokeratin 18 (CK18) is an intermediate filament protein of the cytokeratin acidic type I group and is primarily expressed in single-layered or “simple” epithelial tissues and carcinomas of different origin. Methods To systematically determine CK18 expression in normal and cancerous tissues, 11,952 tumor samples from 115 different tumor types and subtypes (including carcinomas, mesenchymal and biphasic tumors) as well as 608 samples of 76 different normal tissue types were analyzed by immunohistochemistry in a tissue microarray format. Results CK18 was expressed in normal epithelial cells of most organs but absent in normal squamous epithelium. At least an occasional weak CK18 positivity was seen in 90 of 115 (78.3%) tumor types. Wide-spread CK18 positivity was seen in 37 (31.9%) of tumor entities, including adenocarcinomas of the lung, prostate, colon and pancreas as well as ovarian cancer. Tumor categories with variable CK18 immunostaining included cancer types arising from CK18 positive precursor cells but show CK18 downregulation in a fraction of cases, tumor types arising from CK18 negative precursor cells occasionally exhibiting CK18 neo-expression, tumors derived from normal tissues with variable CK18 expression, and tumors with a mixed differentiation. CK18 downregulation was for example seen in renal cell cancers and breast cancers, whereas CK18 neo-expression was found in squamous cell carcinomas of various origins. Down-regulation of CK18 in invasive breast carcinomas of no special type and clear cell renal cell carcinomas (ccRCC) was related to adverse tumor features in both tumors (p ≤ 0.0001) and poor patient prognosis in ccRCC (p = 0.0088). Up-regulation of CK18 in squamous cell carcinomas was linked to high grade and lymph node metastasis (p < 0.05). In summary, CK18 is consistently expressed in various epithelial cancers, especially adenocarcinomas. Conclusions Down-regulation or loss of CK18 expression in cancers arising from CK18 positive tissues as well as CK18 neo-expression in cancers originating from CK18 negative tissues is linked to cancer progression and may reflect tumor dedifferentiation.

• Publisher: BioMed Central,Springer Nature B.V,BMC
• Subject: Antibodies / Biomedical and Life Sciences / Biomedicine / Breast cancer / Cell cycle / Cytokeratin / Cytokeratin 18 (CK18) / Esophagus / Immunohistochemistry / Keratin / Kidney cancer / Kinases / Lung cancer / Lymphatic system / Molecular Medicine / Ovarian cancer / Ovaries / Pathology / Prostate / Research Article / Squamous cell carcinoma / Thymus gland / Tissue microarray / Tumors